Benicar: profile and news

Replidyne and Forest Laboratories Announce FDA Acceptance for ...  Feb 23, 2006
HCl), an N- methyl-D-aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Benicar(R) * (olmesartan ... - Finanzen.net,

Forest Laboratories Receives Patent Term Extension for Lexapro  Mar 4, 2006
Lexapro is one of the fastest growing SSRI antidepressant in the United States. Benicar has become an important treatment option for hypertension. ... - ag-IP-news Agency,

Replidyne and Forest Laboratories Announce Faropenem Medoxomil ...  Feb 13, 2006
HCl), an N- methyl-D-aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Benicar(R)* (olmesartan ... - PR Newswire (press release),

Insurers get between doc, his patients  Feb 26, 2006
Then the Cozaar, Micardis, Benicar and Avapro reps all come and tell me the same thing about their ARB product. What to do about it is the question. ... - The Free Lance-Star,

UPDATE 2-US FDA warns Daiichi Sankyo unit on drug claims  Jan 11, 2006
...(4568.T: Quote, Profile, Research) unit made misleading claims about its anti-hypertension drug Benicar in its sales material, US regulators charged in a ... - Reuters

UPDATE 1-US FDA warns Sankyo on hypertension drug claims  Jan 11, 2006
WASHINGTON, Jan 11 (Reuters) - Sankyo Co. Ltd. (4501.T: Quote, Profile, Research) made misleading claims about its anti-hypertension drug Benicar in its sales ... - Reuters

Forest Laboratories, Inc. Reports Q3'06 Diluted Earnings Per Share ...  Jan 17, 2006
Other income included earnings from the co-promotion agreement with Sankyo Pharma for Benicar(R)* and Benicar HCT(R), antihypertensive therapies, of ... - MSN Money

Hundreds Of Medicine Samples Found On Trail  Jan 26, 2006
Wednesday. Some of the medications included Vioxx, Celebrez, Imitrex, Paxil, Toprol, Topamax, Benicar and Triaz, police said. The ... - Allentown Morning Call,

CORRECTED - US FDA warns Daiichi Sankyo unit on drug claims  Jan 11, 2006
...made misleading claims about its anti-hypertension drug Benicar in a sales material, US regulators charged in a letter made public on Wednesday. ... - Reuters

UPDATE 2-Forest Labs quarterly profit falls 25 percent  Jan 17, 2006
New York-based Forest is counting on newer drugs, high blood pressure drug Benicar and Alzheimer's treatment Namenda, to offset the drop in antidepressant sales ... - Reuters

Forest Laboratories, Inc. Reports Q3'06 Diluted Earnings Per Share ...  Jan 17, 2006
Other income included earnings from the co-promotion agreement with Sankyo Pharma for Benicar®* and Benicar HCT®, antihypertensive therapies, of $28,290,000 ... - Yahoo! News (press release)

Mylan Laboratories and Forest Laboratories Announce Nebivolol ...  Jan 12, 2006
HCl), an N- methyl-D-aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Benicar(R) * (olmesartan ... - PharmaLive.com (press release),

Forest Labs net income down by 25%  Jan 18, 2006
Other income included earnings of $28 million from the co-promotion agreement with Sankyo Pharma for Benicar and Benicar HCT, antihypertensive therapies. ... - Pharmaceutical Business Review

Daiichi Sankyo: pipeline filling at the O-KAI Corral  Jan 11, 2006
...its cardiovascular franchise on bringing antiplatelet therapy CS-747 (prasugrel) to market and driving sales of antihypertensive Benicar/Olmetec (olmesartan ... - Pharmaceutical Business Review

UPDATE 3-Takeda, other Japan drug makers post strong Q3  Jan 31, 2006
Sankyo boosted its full-year recurring profit forecast by 15 percent on Tuesday, citing strong demand for hypertension drug Olmetec, known as Benicar in the ... - Reuters

KAI Pharmaceuticals, Inc. and Sankyo Company, Limited Enter Global ...  Jan 9, 2006
...to build on its strong tradition of significant contributions to the treatment of cardiovascular disease, with products such as Benicar® and Olmetec ... - Yahoo! News (press release)

KAI Pharmaceuticals, Inc. and Sankyo Company, Limited Enter Global ...  Jan 9, 2006
...the opportunity to build on its strong tradition of significant contributions to the treatment of cardiovascular disease, with products such as Benicar(R) and ... - PR Newswire (press release),

25 trash bags of medications dumped  Jan 27, 2006
Among medications found in the bags were: Vioxx, Celebrex, Spiriva, Imitrex, Neurontin, Bextra, Paxil, Toprol, Mobic, Maxalt, Topamax, Benicar and Triaz. ... - Pocono Record,

Forest's Quarterly Profit Falls on Antidepressant Competition  Jan 17, 2006
The company sells Celexa and Lexapro through an agreement with Denmark's H. Lundbeck A/S. Forest acquired rights to its Benicar blood-pressure drug from ... - Bloomberg

Gedeon Richter and Forest Laboratories Expand Relationship with ...  Nov 28, 2005
HCl), an N-methyl-D-aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Benicar®* (olmesartan medoxomil ... - Yahoo! News (press release)

Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce ...  Sep 28, 2005
HCl), an N-methyl-D-aspartate (NMDA)- receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Benicar®*(olmesartan medoxomil ... - Yahoo! News (press release)

New Survey Results from the Community Anti-Drug Coalitions of ...  Sep 29, 2005
...indicated for the treatment of moderate to severe Alzheimer's disease; Celexa(R) (citalopram HBr), an antidepressant for adults; Benicar(R) * (olmesartan ... - PR Newswire (press release),

Oral Solution Formulation of Namenda(R), the Only FDA-Approved ...  Aug 18, 2005
HCl), an N-methyl-D-aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Benicar(R)*(olmesartan medoxomil ... - PR Newswire (press release),

Forest Laboratories, Inc. Reports Fiscal First Quarter 2006 ...  Jul 19, 2005
Also included in net revenues was other income of $37,113,000 which includes $24,267,000 in earnings contribution from the Benicar®* (olmesartan medoxomil) co ... - Yahoo News (press release)

Forest Laboratories Announces FDA Decision on Supplemental New ...  Jul 25, 2005
HCl), an N-methyl-D-aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Benicar®* (olmesartan medoxomil ... - Yahoo News (press release)

Water Pills and Night Sweats  Jul 19, 2005
Combination drugs include Aldoril, Atacand HCT, Avalide, Benicar HCT, Diovan HCT, Dyazide, Hyzaar, Lotensin HCT, Maxzide, Micardis HCT, Moduretic, Prinzide ... - Saturday Evening Post

Forest Labs Shares Could See 'Positive Momentum'  Jul 26, 2005
...with generic Celexa and Cymbalta from Eli Lilly (nyse: LLY - news - people ) on the market as well as continued growth of Namenda and Benicar, Morgan Stanley ... - Forbes

UPDATE 2-Forest Labs net hit by generic competition  Jul 19, 2005
Solomon said key promoted products Lexapro, Namenda for Alzheimer's and Benicar for hypertension, helped to offset losses from Celexa. ... - Reuters

Forest Lab earnings down  Jul 20, 2005
...chairman Howard Solomon said continued strong sales of Lexapro for depression and adult anxiety disorder, Namenda for Alzheimer's and Benicar for hypertension ... - Newsday

UPDATE 3-Forest Labs net hit by generic competition  Jul 19, 2005
...million. Key products Lexapro, Namenda for Alzheimer's and Benicar for hypertension, helped to offset losses from Celexa, he said. ... - Reuters

No significant drug interactions were reported in studies in which olmesartan medoxomil was co-administered with digoxin or warfarin in healthy volunteers. The bioavailability of olmesartan was not significantly altered by the co-administration of antacids [Al(OH)₃/Mg(OH)₂]. Olmesartan medoxomil is not metabolized by the cytochrome P450 system and has no effects on P450 enzymes; thus, interactions with drugs that inhibit, induce or are metabolized by those enzymes are not expected.